Xenical Rx-To-OTC Switch In The Works, GSK/Roche Announce
This article was originally published in The Tan Sheet
Executive Summary
Roche and GlaxoSmithKline appear to be moving quickly on an Rx-to-OTC switch application for the anti-obesity agent Xenical (orlistat)
You may also be interested in...
Short-Term Xenical Treatment Benefits “Difficult To Define,” FDA Says
Efficacy concerns surrounding GlaxoSmithKline's Xenical (orlistat) may prove to be a bigger hurdle to overcome than safety or self-selection issues as the firm pursues an Rx-to-OTC switch of the drug
Short-Term Xenical Treatment Benefits “Difficult To Define,” FDA Says
Efficacy concerns surrounding GlaxoSmithKline's Xenical (orlistat) may prove to be a bigger hurdle to overcome than safety or self-selection issues as the firm pursues an Rx-to-OTC switch of the drug
Short-Term Xenical Treatment Benefits “Difficult To Define,” FDA Says
Efficacy concerns surrounding GlaxoSmithKline's Xenical (orlistat) may prove to be a bigger hurdle to overcome than safety or self-selection issues as the firm pursues an Rx-to-OTC switch of the drug